Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc., which is headquartered in Vancouver, Canada.

Achieve Life Sciences Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on C4 Therapeutics (CCCC) and Achieve Life Sciences (AC...

Wall Street Analysts Are Bullish on Top Healthcare Picks

In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Achieve Life Sciences, with a price target of $12.00. Ac...

Market Cap	$256.06M	P/E Ratio	N/A
52W High	$6.15	52W Low	$2.00
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	32.1%	52W Position	61.7%
Overall Score	35	Value Score	40
Quality Score	13	Technical Score	54

EPS Current Est	$-0.91	EPS Next Est	$-0.63
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ACHV	$4.56	-2.77%	778.11K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ACHV	$4.56	-2.8%	778.11K
3
4
5
6

ACHV

ACHV

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Achieve Life Sciences Inc. Data in Excel

Get Achieve Life Sciences Inc. Data in Excel